Anything rare is possible: Letrozole induced eczematous skin eruption

Amruta Tripathy, K. Meena Kumari, A. V. Mohan Babu, B. Sathish Pai, D. Mahesh Kumar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Letrozole is used as first line drug in postmenopausal women with early-stage or advanced hormone-sensitive breast cancer. Letrozole has favourable tolerability profile when administered once daily and significant adverse reactions occur rarely. The objective of this report is to describe a case of eczematous skin eruption that occurred during letrozole treatment. A 61-year-old female patient was admitted with lump in the left breast. FNAC, HPE were done and the patient was diagnosed to have invasive ductal breast carcinoma. After a month of completing CT and EBRT, the patient was given 2.5 mg OD tab. letrozole at night. She developed itchy skin lesions over the right thigh that later generalised, at 6- weeks of treatment. The lesion has been defined as eczematous moderate to severe drug eruption. These lesions were attributed to letrozole therapy and recurred within 24h after rechallenge. Drug eruption is associated with many drugs but this is the first such report with letrozole. We suggest of being aware of such reactions during letrozole usage.

Original languageEnglish
JournalJournal of Clinical and Diagnostic Research
Volume8
Issue number6
DOIs
Publication statusPublished - 20-06-2014

Fingerprint

letrozole
Skin
Drug Eruptions
Pharmaceutical Preparations
Carcinoma, Ductal, Breast
Thigh

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

@article{60f621d877a5480cb8a0cca1d7c4d325,
title = "Anything rare is possible: Letrozole induced eczematous skin eruption",
abstract = "Letrozole is used as first line drug in postmenopausal women with early-stage or advanced hormone-sensitive breast cancer. Letrozole has favourable tolerability profile when administered once daily and significant adverse reactions occur rarely. The objective of this report is to describe a case of eczematous skin eruption that occurred during letrozole treatment. A 61-year-old female patient was admitted with lump in the left breast. FNAC, HPE were done and the patient was diagnosed to have invasive ductal breast carcinoma. After a month of completing CT and EBRT, the patient was given 2.5 mg OD tab. letrozole at night. She developed itchy skin lesions over the right thigh that later generalised, at 6- weeks of treatment. The lesion has been defined as eczematous moderate to severe drug eruption. These lesions were attributed to letrozole therapy and recurred within 24h after rechallenge. Drug eruption is associated with many drugs but this is the first such report with letrozole. We suggest of being aware of such reactions during letrozole usage.",
author = "Amruta Tripathy and {Meena Kumari}, K. and {Mohan Babu}, {A. V.} and {Sathish Pai}, B. and {Mahesh Kumar}, D.",
year = "2014",
month = "6",
day = "20",
doi = "10.7860/JCDR/2014/9028.4498",
language = "English",
volume = "8",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "6",

}

Anything rare is possible : Letrozole induced eczematous skin eruption. / Tripathy, Amruta; Meena Kumari, K.; Mohan Babu, A. V.; Sathish Pai, B.; Mahesh Kumar, D.

In: Journal of Clinical and Diagnostic Research, Vol. 8, No. 6, 20.06.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anything rare is possible

T2 - Letrozole induced eczematous skin eruption

AU - Tripathy, Amruta

AU - Meena Kumari, K.

AU - Mohan Babu, A. V.

AU - Sathish Pai, B.

AU - Mahesh Kumar, D.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - Letrozole is used as first line drug in postmenopausal women with early-stage or advanced hormone-sensitive breast cancer. Letrozole has favourable tolerability profile when administered once daily and significant adverse reactions occur rarely. The objective of this report is to describe a case of eczematous skin eruption that occurred during letrozole treatment. A 61-year-old female patient was admitted with lump in the left breast. FNAC, HPE were done and the patient was diagnosed to have invasive ductal breast carcinoma. After a month of completing CT and EBRT, the patient was given 2.5 mg OD tab. letrozole at night. She developed itchy skin lesions over the right thigh that later generalised, at 6- weeks of treatment. The lesion has been defined as eczematous moderate to severe drug eruption. These lesions were attributed to letrozole therapy and recurred within 24h after rechallenge. Drug eruption is associated with many drugs but this is the first such report with letrozole. We suggest of being aware of such reactions during letrozole usage.

AB - Letrozole is used as first line drug in postmenopausal women with early-stage or advanced hormone-sensitive breast cancer. Letrozole has favourable tolerability profile when administered once daily and significant adverse reactions occur rarely. The objective of this report is to describe a case of eczematous skin eruption that occurred during letrozole treatment. A 61-year-old female patient was admitted with lump in the left breast. FNAC, HPE were done and the patient was diagnosed to have invasive ductal breast carcinoma. After a month of completing CT and EBRT, the patient was given 2.5 mg OD tab. letrozole at night. She developed itchy skin lesions over the right thigh that later generalised, at 6- weeks of treatment. The lesion has been defined as eczematous moderate to severe drug eruption. These lesions were attributed to letrozole therapy and recurred within 24h after rechallenge. Drug eruption is associated with many drugs but this is the first such report with letrozole. We suggest of being aware of such reactions during letrozole usage.

UR - http://www.scopus.com/inward/record.url?scp=84903126757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903126757&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2014/9028.4498

DO - 10.7860/JCDR/2014/9028.4498

M3 - Article

AN - SCOPUS:84903126757

VL - 8

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 6

ER -